Defining Value for the Treatment of Brain Metastases in Metastatic HER2-Positive Breast Cancer

Sarah Sammons, MD

Sarah Sammons, MD, provides an overview of the progression HER2-positive metastatic breast cancer [mBC] and common areas for the development of metastases, including in the brain.

Sarah Sammons, MD

Insights on diagnosing patients who have HER2+ metastatic breast cancer with brain metastases based on current NCCN Guidelines recommendations when they may present with them during the course of treatment, and the impact on quality of life.

Kevin M. Kalinsky, MD, MD

Kevin M. Kalinsky, MD, MS, discusses monitoring patients with HER2-positive mBC who have asymptomatic brain metastases and advancements in therapy for HER2-positive disease leading to increased brain metastases.

Sarah Sammons, MD

EP. 7: HER2CLIMB Study

A review of the HER2CLIMB study using oral the TKI tucatinib as therapy for HER2-positive metastatic breast cancer.

Sarah Sammons, MD

Sarah Sammons, MD, and Kevin M. Kalinsky, MD, MS, review the phase 2 LANDSCAPE trial using lapatinib for patients with HER2+ mBC and a history of brain metastases.

Kevin M. Kalinsky, MD, MS

EP. 9: Phase 3 NALA Study

A review of the NALA study looking at the use of capecitabine plus neratinib in patients with pretreated metastatic HER2-positive breast cancer.

Sarah Sammons, MD

Kevin M. Kalinsky, MD, MS, and Sarah Sammons, MD, review the phase 2 single-arm trial DESTINY-Breast01, exploring the use of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer.

Bhavesh Shah, RPh, BCOP

A payer perspective on the impact of early identification of brain mets in HER2+ metastatic breast cancer on healthcare utilization and patient outcomes as well as recommendations to other payers managing this patient population.

Sarah Sammons, MD

The impact of COVID-19 on the treatment of metastatic breast cancer in regard to site of care and utilization of telehealth, as well as the evolving treatment landscape with emerging agents in the pipeline.

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo